New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Although chimeric antigen receptor T (CAR-T) cell therapy has proven to be effective in treating relapsed or refractory B-cell hematological malignancies, severe hematological toxicities remain an intractable issue. This retrospective study assessed the characteristics and risk factors of new-onset...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Linqin, Hong, Ruimin, Zhou, Linghui, Ni, Fang, Zhang, Mingming, Zhao, Houli, Wu, Wenjun, Wang, Yiyun, Ding, Shuyi, Chang, Alex H., Hu, Yongxian, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278328/
https://www.ncbi.nlm.nih.gov/pubmed/34277448
http://dx.doi.org/10.3389/fonc.2021.702644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278328/
https://www.ncbi.nlm.nih.gov/pubmed/34277448
http://dx.doi.org/10.3389/fonc.2021.702644

Ejemplares similares